Clinical resource
Head and neck glottic larynx squamous cell carcinoma definitive EBRT (eviQ ID 584)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for early-stage glottic larynx cancer treated with radiotherapy alone. Its target volumes cover the larynx only, without elective nodes, and it notes the effect of swallowing on larynx position.
Why this is useful
Small-field radiotherapy for early (Tis–T2 N0) glottic cancer: moderately hypofractionated schedules, no elective neck and larynx-only target volumes.
Reference details
- Title
- Head and neck glottic larynx squamous cell carcinoma definitive EBRT (eviQ ID 584)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 584
- Version
- v.5 — last reviewed 30 April 2026; review due 30 June 2030
- Year
- 2026
- DOI
- Pending verification
- Disease sites
- Head & Neck
- Topics
- Head & Neck, Dose Constraints, Protocols
- Fractionation context
- Tis–T1: 63 Gy / 28 fx or 60 Gy / 25 fx; T2: 66–70 Gy / 33–35 fx, 65.25 Gy / 29 fx or 64.8 Gy / 27 fx
- Last reviewed by DoseLab
- 2026-09-24